[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of alogliptin benzoate tablets (25 mg) in Chinese healthy subjects under fasting conditions

主要研究目的：按有关生物等效性试验的规定，选择Takeda Pharmaceutical Company Limited为持证商的苯甲酸阿格列汀片（商品名：尼欣那，规格：25mg）为参比制剂，对石家庄四药有限公司生产并提供的受试制剂苯甲酸阿格列汀片（规格：25mg）进行空腹给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评价两种制剂在空腹给药条件下的生物等效性。次要研究目的：观察健康受试者口服受试制剂苯甲酸阿格列汀片（规格：25mg）和参比制剂苯甲酸阿格列汀片（商品名：尼欣那，规格：25mg）的安全性。

[Translation]

Main purpose of study: According to the relevant provisions of bioequivalence test, Takeda Pharmaceutical Company Limited was selected as the reference preparation for alogliptin benzoate tablets (trade name: Nisina, specification: 25mg), and the test preparation alogliptin benzoate tablets (specification: 25mg) produced and provided by Shijiazhuang Siyao Co., Ltd. was used for fasting human bioequivalence test, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting conditions. Secondary purpose of study: To observe the safety of oral administration of the test preparation alogliptin benzoate tablets (specification: 25mg) and the reference preparation alogliptin benzoate tablets (trade name: Nisina, specification: 25mg) in healthy subjects.

Start Date24 Mar 2025

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

CTR20250729

/ CompletedNot Applicable

苯甲酸阿格列汀片（25mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

主要研究目的：按有关生物等效性试验的规定，选择Takeda Pharmaceutical Company Limited为持证商的苯甲酸阿格列汀片（商品名：尼欣那，规格：25mg）为参比制剂，对石家庄四药有限公司生产并提供的受试制剂苯甲酸阿格列汀片（规格：25mg）进行餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评价两种制剂在餐后给药条件下的生物等效性。次要研究目的：观察健康受试者口服受试制剂苯甲酸阿格列汀片（规格：25mg）和参比制剂苯甲酸阿格列汀片（商品名：尼欣那，规格：25mg）的安全性。

[Translation]

Main purpose of study: According to the relevant provisions of bioequivalence test, Takeda Pharmaceutical Company Limited was selected as the reference preparation for alogliptin benzoate tablets (trade name: Nisina, specification: 25mg), and the test preparation alogliptin benzoate tablets (specification: 25mg) produced and provided by Shijiazhuang Siyao Co., Ltd. was used for human bioequivalence test after meal administration. The difference between the absorption rate and absorption extent of the drug in the test preparation and the reference preparation was compared to see whether it was within an acceptable range, and to evaluate the bioequivalence of the two preparations under the condition of postprandial administration. Secondary purpose of study: To observe the safety of oral administration of the test preparation alogliptin benzoate tablets (specification: 25mg) and the reference preparation alogliptin benzoate tablets (trade name: Nisina, specification: 25mg) to healthy subjects.

Start Date23 Mar 2025

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

CTIS2025-520460-18-00

/ Not yet recruitingPhase 1

- BLCL-AE-EU-02

Start Date18 Feb 2025

Sponsor / Collaborator

Tecnimede Sociedade Tecnico Medicinal SA

100 Clinical Results associated with Alogliptin Benzoate

100 Translational Medicine associated with Alogliptin Benzoate

100 Patents (Medical) associated with Alogliptin Benzoate

1,061

Literatures (Medical) associated with Alogliptin Benzoate

02 May 2025·JOURNAL OF PHARMACY AND PHARMACOLOGY

Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico, in vitro, and in vivo analysis

Article

Author: Najmi, Abul Kalam ; Krishnan, Anuja ; Ahmed, Faraha ; Altamish, Mohammad ; Ahmad, Syed Sufian ; Alam, Mohammad Mumtaz ; Vohora, Divya ; Khan, Mohammad Ahmed ; Shaquiquzzaman, Mohammad

Abstract:

Objective:

To investigate the effects of Alogliptin in chemical-induced post-menopausal osteoporosis.

Methodology:

The binding affinity of alogliptin with osteogenic proteins was analysed in silico. The effect of alogliptin on osteogenic proteins and mineralization of osteoblastic cells was evaluated in UMR-106 cells. Further, in vivo anti-osteoporotic activity of alogliptin was evaluated in postmenopausal osteoporosis. Various bone turnover markers were assayed in serum. This followed the analysis of microarchitecture of bone, histology, and immunohistochemistry (IHC) of bone tissue.

Results:

Docking scores showed that alogliptin has binding affinity for bone alkaline phosphatase (BALP), osteocalcin, and bone morphogenic protein (BMP-2). Alogliptin also enhanced mineralization of osteoblast cells, evidenced with increased ALP, osteocalcin, and BMP-2. Animal studies revealed significant elevation of bone formation markers, bone ALP, osteocalcin and BMP-2, and decreased bone resorption markers, receptor activator of NF-κβ (RANKL), cathepsin K (CTSK), tartrate resistant acid phosphatase (TRAcP5b) in VCD-induced post-menopausal osteoporosis. Micro computed tomography (μCT) analysis and histology of femur bone and lumbar vertebrae demonstrated decrease in trabecular separation and improved bone density. IHC of femur showed reduced DPP4 enzyme.

Conclusions:

Alogliptin increased mineralization in osteoblast cells. It had beneficial effects also altered bone turnover markers, repaired the trabecular microstructure, improved bone mineral density, and exhibited bone forming capacity targeting DPP-4 enzyme in postmenopausal osteoporosis.

01 May 2025·Diabetes Therapy

A Randomized Phase 3 Study Evaluating the Efficacy and Safety of Alogliptin in Pediatric Participants with Type 2 Diabetes Mellitus

Article

Author: Klingensmith, Georgeanna ; Peng, Xuejun Victor ; Xie, Yunlong ; Tamborlane, William V ; Hsia, Daniel S ; Shah, Amy S ; Czerniak, Richard

INTRODUCTION:

There is an unmet need for pharmacological therapies for children with type 2 diabetes mellitus (T2DM). We assessed the efficacy and safety of an oral dipeptidyl peptidase-4 inhibitor, alogliptin, 25 mg once daily (QD), as a potential treatment for pediatric patients with T2DM.

METHODS:

This phase 3, 52-week, multicenter, randomized, double-blind, placebo-controlled trial was conducted in children and adolescents (10-17 years old) with T2DM. Participants had glycosylated hemoglobin (HbA1c) ≥ 6.5% at baseline (≥ 6.5% to < 11% without treatment or on metformin alone; ≥ 7.0% to < 11% on insulin alone or in combination with metformin). Where required, participants underwent prerandomization stabilization of their background metformin and/or insulin therapy. All received diabetes education and home glucose-monitoring training (during screening, prerandomization stabilization, and specified visits through week 26). Participants were then stratified based on previous antihyperglycemic therapy for 12 weeks before screening into schedule A (antihyperglycemic treatment-naïve) or B (metformin and/or insulin). The primary efficacy endpoint was change in HbA1c levels from baseline at week 26. Safety was assessed as a secondary endpoint at week 52.

RESULTS:

Overall, 152 participants (median age, 14 years; 68.9% female) were randomized (1:1) to receive either alogliptin (n = 75) or placebo (n = 77). The majority were white (58.3%), had a body mass index of ≥ 30 kg/m² (60.3%), and had received previous antihyperglycemic therapy (82.1%). The difference in HbA1c levels from baseline to week 26 between the alogliptin and placebo groups (least squares mean change [95% confidence interval]) was 0.10 (- 0.63, 0.83; p = 0.78). There was no difference in efficacy endpoints between alogliptin and placebo across both subgroups. No new safety concerns were observed with alogliptin treatment.

CONCLUSION:

Alogliptin 25 mg QD did not significantly improve glycemic control versus placebo in pediatric patients with T2DM. Alogliptin treatment was safe and well tolerated, and no new safety concerns were observed in this study.

TRIAL REGISTRATION:

ClinicalTrials.gov: NCT02856113; EudraCT: 2015-000208-25.

02 Apr 2025·ACS Chemical Neuroscience

Upregulation of the PI3K/AKT and Nrf2 Pathways by the DPP-4 Inhibitor Sitagliptin Renders Neuroprotection in Chemically Induced Parkinson’s Disease Mouse Models

Article

Author: Pankaj, Vaishali ; Khairnar, Amit ; Shah, Jigna ; Roy, Sudeep ; Soni, Ritu

Parkinson's disease (PD) is one of the most common progressive neurodegenerative pathologies that leads to dopaminergic deficiency and motor manifestations. Alpha-synuclein aggregation is a characteristic hallmark of PD pathogenesis. These aggregates facilitate the formation of Lewy bodies and degeneration. The epidemiological evidence demonstrates a definitive association of diabetes with PD risk. Considering this, many antidiabetic agents such as GLP-1 agonists and DPP-4 inhibitors are being explored as alternative PD therapeutics. This study evaluated the neuroprotective effect of the DPP-4 inhibitor sitagliptin mediated by the PI3K/AKT and Nrf2 pathways in PD models. In silico studies were conducted to determine the binding affinity, stability, and ADMET properties of DPP-4 inhibitors with target proteins. Sitagliptin (15 mg/kg p.o.) was administered in rotenone (30 mg/kg p.o. for 28 days)-induced and MPTP/P (25 mg/kg i.p. MPTP and 100 mg/kg probenecid i.p. twice a week for 5 weeks)-induced PD mouse (C57/BL6) models. Neurobehavioral assessments were carried out throughout the study. Biochemical (GSH, MDA), molecular estimations (AKT, Nrf2, PI3K, GSK-3β, GLP1, CREB, BDNF, NF-κB, alpha-synuclein), histopathological studies, and immunohistochemistry were carried out at the end of the study. The in silico studies demonstrate better binding, stability, and ADMET profile of sitagliptin with both target proteins. Sitagliptin restored cognitive and motor deficits in both rotenone- and MPTP/P-induced mouse models. There was upregulation of PI3K, AKT, Nrf2, CREB, and BDNF levels and downregulation of GSK-3β, NF-κB, and alpha-synuclein levels in both models after treatment with sitagliptin. However, GLP1 levels were not significantly restored, indicating a GLP1-independent mechanism. It also restored histopathological alterations and TH+ neuronal loss induced by rotenone and MPTP/P. These findings demonstrate that sitagliptin exhibits neuroprotective action mediated by upregulation of the PI3K/AKT and Nrf2 pathways in rotenone and MPTP/P mouse models of PD.

News (Medical) associated with Alogliptin Benzoate

23 May 2025

·pharma.economictimes.indiatimes.com

GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks

London: Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk 's Ozempic may modestly reduce the risk of obesity-related cancers, especially colorectal cancer , according to data released on Thursday ahead of a major medical meeting. Among more than 85,000 people with type 2 diabetes and obesity treated between 2013 and 2023 and followed for an average of nearly four years, 2,501 obesity-related cancers developed in those taking GLP-1 diabetes drugs , compared with 2,671 such cancers in those treating their diabetes with drugs from a class known as DPP-4 inhibitors . After accounting for individual risk factors, those taking GLP-1 drugs had a 7 per cent lower risk of developing an obesity-related cancer and an 8 per cent lower risk of death from any cause compared to those who took a DPP-4 inhibitor, a brief summary of data to be presented at the upcoming American Society of Clinical Oncology meeting in Chicago showed. The effect was only statistically significant in women, researchers said. Other GLP-1 drugs for improving blood glucose control taken by patients in the study include Eli Lilly's Trulicity and Novo's Victoza and Rybelsus, among others. These drugs deliver a lower dose of their main ingredient compared to GLP-1 drugs designed to induce weight loss. DPP-4 inhibitors include Merck & Co's Januvia and Nesina from Takeda Pharmaceuticals. While a modestly reduced risk for 14 obesity-related cancers was evident with GLP-1 drugs, the suggestion of a protective effect was particularly strong for colorectal malignancies. There were 16 per cent fewer colon cancer cases and 28 per cent fewer rectal cancer cases in the group prescribed GLP-1 receptor agonists. Observational studies like this cannot prove that the GLP-1 drugs caused lower cancer rates. "These data are reassuring, but more studies are required to prove causation," lead study author Lucas Mavromatis, a medical student at the NYU Grossman School of Medicine in New York, said in a statement. (Reporting by Nancy Lapid; Editing by Bill Berkrot)

ASCOClinical Result

14 Feb 2024

·endpts.com

Appeals court sides with AstraZeneca, BMS, McKesson in saxagliptin heart failure case

A Sixth Circuit appeals court this week upheld a decision in favor of AstraZeneca, Bristol Myers Squibb and McKesson in a case alleging that diabetes products containing saxagliptin can cause heart failure. Saxagliptin is the key ingredient in the discontinued type 2 diabetes treatments Onglyza and Kombiglyze. It’s a dipeptidyl peptidase-4 (DPP-4) inhibitor, designed to help lower blood sugar along with diet and exercise. But in 2016, an FDA safety review found that saxagliptin and another DPP-4 inhibitor called alogliptin may increase patients’ risk of heart failure. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Patent Infringement

24 Nov 2023

·synapse.patsnap.com

What are DPP-4 inhibitors and how do you quickly get the latest development progress?

Dipeptidyl peptidase-4 (DPP-4) is an enzyme found in the human body that plays a crucial role in regulating glucose metabolism. It is primarily expressed in the pancreas, intestines, and immune cells. DPP-4 is responsible for breaking down incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are released after a meal to stimulate insulin secretion and reduce blood sugar levels. By inhibiting DPP-4 activity, pharmaceutical drugs can prolong the action of these incretin hormones, leading to increased insulin release, improved glycemic control, and potential therapeutic benefits for individuals with type 2 diabetes. Several dozens of DPP-4 inhibitors have been introduced to the market, with sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin being available in domestic markets. DPP-4 inhibitors can be combined with multiple antidiabetic drugs to form fixed-dose combinations, among which, the combinations with metformin are most common. The currently available DPP-4 inhibitor-metformin fixed-dose combinations in the domestic market include sitagliptin/metformin tablets, vildagliptin/metformin tablets, saxagliptin/metformin extended-release tablets, linagliptin/metformin tablets. DPP-4 inhibitors can be used as monotherapy for type 2 diabetes and can also be combined with other antidiabetic drugs for the treatment of type 2 diabetes. The most commonly combined antidiabetic drugs with DPP-4 inhibitors are metformin, followed by sulfonylureas, thiazolidinediones, and insulin. They can also be used in combination with two other antidiabetic drugs, forming a triple therapy commonly including combinations of DPP-4 inhibitors + metformin + sulfonylureas, DPP-4 inhibitors + metformin + thiazolidinediones, and DPP-4 inhibitors + metformin + insulin. The analysis of the target DPP-4 in the pharmaceutical industry reveals a competitive landscape with several companies focusing on the development of DPP-4 inhibitors. Merck & Co., Inc., Takeda Pharmaceutical Co., Ltd., C.H. Boehringer Sohn AG & Co. KG, LG Chem Ltd., and AstraZeneca PLC are among the companies growing fastest under this target. The primary indication for the approved drugs is diabetes mellitus, type 2. Small molecule drugs are progressing most rapidly, indicating intense competition around the innovative drug. The United States, European Union, Japan, and China are the countries/locations developing fastest under this target, with China showing significant progress. Overall, the target DPP-4 presents opportunities for further research and development in the treatment of diabetes and related indications. Unlocking Blood Sugar Control: The Role of DPP-4 Inhibitors in Type 2 Diabetes ManagementDPP-4 inhibitors, also known as dipeptidyl peptidase-4 inhibitors, are a type of medication used in the treatment of type 2 diabetes. From a biomedical perspective, DPP-4 inhibitors work by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for breaking down incretin hormones in the body. Incretin hormones play a role in regulating blood sugar levels by stimulating the release of insulin and reducing the production of glucagon. By inhibiting DPP-4, these medications increase the levels of incretin hormones, leading to improved blood sugar control. DPP-4 inhibitors are typically taken orally and are often prescribed as an adjunct to diet and exercise in the management of type 2 diabetes. They can be used as monotherapy or in combination with other antidiabetic medications, such as metformin. Some common examples of DPP-4 inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin. These medications have been shown to be effective in lowering blood sugar levels and have a favorable safety profile. It's important to note that DPP-4 inhibitors are not recommended for the treatment of type 1 diabetes or diabetic ketoacidosis. They are primarily used in the management of type 2 diabetes and can help improve glycemic control in individuals with this condition. As with any medication, DPP-4 inhibitors may have potential side effects, and it is essential to consult with a healthcare professional for proper evaluation and monitoring while taking these medications. Catalog of DPP-4 InhibitorsThe currently marketed DPP-4 inhibitors include: Sitagliptin/Metformin HydrochlorideSitagliptinRetagliptin PhosphateGemigliptin/DapagliflozinMetformin Hydrochloride/Sitagliptin HydrochlorideEmpagliflozin/Linagliptin/Metformin HydrochlorideAnagliptin/Metformin HydrochlorideErtugliflozin/Sitagliptin PhosphateGosogliptinEvogliptinFor more information, please click on the image below. What is the purpose of using DPP-4 inhibitors?DPP-4 inhibitors can be used as a mono-drug treatment for type 2 diabetes, or in combination with other glucose-lowering drugs for the treatment of type 2 diabetes. For more information, please click on the image below to log in and search. How can you get the most recent advancements in DPP-4 inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of DPP-4 inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

100 Deals associated with Alogliptin Benzoate

External Link

KEGG	Wiki	ATC	Drug Bank
D06553	Alogliptin Benzoate	A10BH04	DB06203

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Japan	Takeda Pharmaceutical Co., Ltd.	06 Apr 2010
Diabetes Mellitus, Type 2	Japan	Teijin Pharma Ltd.	06 Apr 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Coronary Syndrome	Phase 3	United States	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Japan	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Argentina	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Australia	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Austria	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Belgium	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Brazil	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Bulgaria	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Canada	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Chile	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02856113 (2015-000208-25, Pubmed \| Diabetes Ther)	Phase 3	Diabetes Mellitus, Type 2	152	Alogliptin 25 mg QD	jjoftfuxzg(aidgzaqaau) = ntpfulamvp srcuabekek (tmjeszbibk, -0.63 to 0.83)	Negative	04 Mar 2025
1340-P (ADA2024)	Not Applicable	Diabetes Mellitus	-	SGLT2i	hgkfftgsoo(yycmpqbwfm) = iieeomrluk pwogchhjvw (vklxkgowyo, 16.6 - 19.7)	Positive	14 Jun 2024
				DPP4i	hgkfftgsoo(yycmpqbwfm) = dpenvukbdr pwogchhjvw (vklxkgowyo, 19.1 - 21.4)
NCT05782192 (Pubmed)	Phase 3	Diabetes Mellitus, Type 2	-	Fotagliptin	hbbckguezk(pbddqzsjgk) = ukslwgxtqe ksiqwdpcte (ugzczpqdyw ) View more	Positive	09 Oct 2023
				Alogliptin	hbbckguezk(pbddqzsjgk) = juplpjugsa ksiqwdpcte (ugzczpqdyw ) View more
NCT02856113 (2015-000208-25, CTgov)	Phase 3	Diabetes Mellitus, Type 2	152	Placebo (Placebo)	ocpwthsdjh(fdijhpvcyk) = ymldjpfunt ggofavkpxy (hxvijwsine, 0.2809) View more	-	19 Oct 2022
				Alogliptin Benzoate (Alogliptin 25 mg)	ocpwthsdjh(fdijhpvcyk) = izuftapbhx ggofavkpxy (hxvijwsine, 0.2879) View more
NCT03794336 (ACADEMIC, Pubmed \| Diabetes Obes Metab) Manual	Phase 4	Diabetes Mellitus, Type 2 \| Coronary Disease	1,088	aspirin+alogliptin	vdmmjgccyz(mnnhaxzjyb) = kkywecgwze ubjcbodhby (mbskqstvxf, 0.4) View more	Positive	03 Feb 2022
				aspirin+acarbose	vdmmjgccyz(mnnhaxzjyb) = macsamjmzl ubjcbodhby (mbskqstvxf, 0.5) View more
NCT03794336 (EASD2021)	Phase 4	Cardiovascular Diseases \| Diabetes Mellitus, Type 2 \| Coronary Disease	-	Alogliptin 25 mg q.d.	kjsvkojprv(uhnxhgfulm) = Significantly lesser GI adverse events were observed with alogliptin than acarbose (8.9% vs 33.6%, P <0.0001) biaokzobjs (qfkgzhgdkk ) View more	Positive	29 Sep 2021
				Acarbose 100 mg t.i.d.
NCT03231709 (TRINITY, CTgov)	Phase 4	Diabetes Mellitus, Type 2	60	Trelagliptin+Alogliptin (Trelagliptin 100 mg + Alogliptin 25 mg)	awhndjqyhp = fmfjcijtfn qeikxkushw (omujxaqtpz, xtnujbuljg - khmnioxuvi) View more	-	10 May 2019
				Trelagliptin+Alogliptin (Alogliptin 25 mg + Trelagliptin 100 mg)	awhndjqyhp = wfnrikecqc qeikxkushw (omujxaqtpz, wvfabetopo - bnyzcyvrzv) View more
NCT02771093 (TRACK, CTgov)	Phase 4	Diabetes Mellitus, Type 2	27	Trelagliptin (Trelagliptin 100 mg)	fytbkddqlk(euifwisqep) = ocjuestkuf rccrpkovmm (horncmiscj, ymtufsnvjp - sbpivjtgdm) View more	-	10 Dec 2018
				Alogliptin (Alogliptin 25 mg)	fytbkddqlk(euifwisqep) = klwavvzhba rccrpkovmm (horncmiscj, wnaywgocxw - evbkmghsds) View more
EASD2018	Not Applicable	Diabetes Mellitus, Type 2	865	Alogliptin	jpftozmckr(zaowecbokn) = bnazmpygnn yjklnbueys (salrkwkauu, 1.62)	Positive	02 Oct 2018
				Sitagliptin	jpftozmckr(zaowecbokn) = lntalsbynd yjklnbueys (salrkwkauu, 1.52)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis